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ABSTRACT 
Background: Both metabolic syndrome (MetS) and NT-proBNP confer increased risk of 
cardiovascular diseases (CVD). We assessed if NT-proBNP levels were greater in people with 
uncomplicated MetS, who had neither CVD/chronic kidney disease (CKD) nor diabetes,  as 
compared to subjects who met none of the defining criteria of the MetS. 
Methods: A case-cohort study from the non-diabetic population-based Casale Monferrato Study 
was performed, after exclusion of all subjects with established CVD, CKD (eGFR<60 
ml/min/1.73m
2
) and CRP values ≥ 3 mg/l. Cases (n=161) with MetS were compared to all subjects 
within the cohort (n=124) who were completely free of any component of the MetS. Serum NT-
proBNP were centrally measured by immunoenzymatic assay.  
Results: NT-proBNP levels were significantly higher in cases than in control subjects [35.4 (15.5-
98.2) vs 24.4 (11.7-49.6) pg/ml, p=0.014]. In logistic regression analysis, compared to NT-proBNP 
values in the lower quartiles (≤49.64 pg/ml), higher values conferred OR 4.17 (1.30-13.44) of 
having the MetS, independently of age, sex, microalbuminuria, CRP, eGFR, and central obesity. 
This association was evident even after the exclusion of hypertensive subjects. Further adjustment 
for log-HOMA and diastolic blood pressure did not modify the strength of the association, while 
central obesity was a negative confounder.  
Conclusions: Compared to people without any component of the MetS, those with uncomplicated 
MetS, who had neither CVD/CKD nor diabetes, had increased NT-proBNP values, even if they 
were normotensive and though absolute values were still in the low range. The insulin-resistance 
state did not mediate this association, while central obesity was a negative confounder.  
 
Keywords: natriuretic peptides, metabolic syndrome, cardiovascular risk, survey, population-based 
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Introduction     
N-amino terminal fragment of the prohormone B-type natriuretic peptide (NT-proBNP), a well-
established biomarker of both left ventricular hypertrophy and heart failure, is associated with an 
increased risk of mortality and cardiovascular disease (CVD) in the general population [1-3]. In 
addition, a recent prospective study has demonstrated that in non-diabetic people NT-proBNP levels 
are inversely and independently associated with an increased risk of having diabetes over a 11-years 
follow-up period, suggesting a direct role of BNP in the regulation of metabolic processes in 
humans [4]. In keeping with this hypothesis receptors for natriuretic peptides have been found in 
the adipose tissue [5] and higher natriuretic peptide levels have been associated with a favorable 
adipose tissue distribution profile [6]. Moreover, studies in experimental animals have shown that 
BNP transgenic mice fed with a high-fat diet exhibit less weight gain, ectopic fat accumulation, and 
insulin resistance [7]. Further, treatment with BNP increases energy expenditure and thermogenic 
activation in both brown and white adipose tissue [8]. The underlying mechanism is still unclear, 
however, it has been proposed that BNP binding to the adipocyte natriuretic peptide receptor 
(NPR)-A activates downstream signalling cascades leading to increased mitochondrial biogenesis 
and uncoupled respiration [7,8]. 
The metabolic syndrome (MetS), which confers an increased risk for both type 2 diabetes 
and CVD, comprises a cluster of metabolic abnormalities with visceral adiposity, insulin resistance, 
and low-grade inflammation as its central pathophysiological features [9]. Therefore, the newly 
discovered role of natriuretic peptides in the control of metabolic processes is of particular 
relevance in patients with MetS [10]. Previous data on NT-proBNP levels in subjects with the MetS 
are conflicting, with studies showing either lower or similar values compared to people without the 
MetS [11-13]. However, given the opposite effect of obesity and CVD on NT-proBNP levels, 
inconsistencies among previous studies might be related to the different prevalence of these 
conditions in the examined populations.  
Therefore, we designed a case-cohort study from the population-based Casale Monferrato 
Study to compare circulating NT-proBNP levels in people with MetS, uncomplicated by CVD and 
chronic kidney disease (CKD), and in subjects who did not meet any of the defining criteria of the 
MetS.   
 
Materials and Methods 
      The Casale Monferrato study is an ongoing population-based study started in 1988 in the town 
of Casale Monferrato, North-West of Italy. A non-diabetic cohort (n=2,211) was recruited in 2005 
from an age- and sex-stratified sample of 3,700 individuals, aged 45-74 years, randomly identified 
through the files of the resident population, after having excluded those with heart failure,  
neoplastic and other chronic diseases, as previously detailed [14]. Subjects were examined at the 
diabetes clinic and blood samples collected after overnight fasting, and stored at -80° C. Ethics 
committee approval was obtained. Informed consent was obtained from all patients for being 
included in the study. All procedures followed were in accordance with the ethical standards of the 
responsible committee on human experimentation (institutional and national) and with the Helsinki 
Declaration of 1975, as revised in 2008. A cross-sectional case-control study was designed from the 
non-diabetic cohort of the Casale Monferrato study, after exclusion of subjects (n=659) with CVD, 
CKD (eGFR<60 ml/min/1.73m
2
), and/or high sensitive C reactive protein (hs-CRP) levels ≥ 3mg/l. 
Cases were those who fulfilled the criteria of the updated National Cholesterol Education Program’s 
Adult Treatment Panel III report for the diagnosis of MetS, therefore they had at least three risk 
factors to sustain the diagnosis, including central obesity, hypertension/antihypertensive 
medications, dyslipidemia (low HDL-cholesterol and high triglycerides), impaired fasting glucose. 
We then identified as control subjects all those subjects who were completely free of any 
component of the MetS. Applying these criteria, this yielded 161 cases and 125 controls with full 
data on complications and samples available for analysis. The sample size provides a power of 80% 
(α=0.05) to detect a difference in log-NTproBNP within the cohort of at least one-third of standard 
deviation (SD). 
    Waist circumference was measured at the midpoint between the lower rib and the iliac crest. 
Smoking status was classified as current smoker, never smoker, ex-smoker (smoking cessation at 
least a month prior to the visit). Hypertension was defined as systolic blood pressure >140 mmHg 
and/or diastolic blood pressure >90 mmHg or treatment with antihypertensive drugs. CVD was 
defined as a positive medical history of a cardiovascular event, including myocardial infarction, 
angina pectoris, coronary artery bypass graft and stroke, and/or ischemic changes on a resting 12-
lead electrocardiogram, classified according to the Minnesota Code. The WHO Rose questionnaire 
was also administered and people with symptoms suggestive of CVD underwent further 
investigations to confirm the diagnosis.   
Fasting blood samples were taken in the morning visit from all recruited subjects and plasma 
glucose levels measured using the glucose-oxidase method. Triglycerides, total-cholesterol, HDL-
cholesterol, apolipoprotein B, serum creatinine and insulin were measured by standard techniques, 
hs-CRP by immunoturbidimetry (Roche-Diagnostic), and albumin excretion rate (AER) by 
nephelometry on single overnight urine collections. Serum insulin was measured by 
radioimmunoassay in the non-diabetic cohort only. The degree of insulin sensitivity was determined 
using the HOMA-IR calculated as fasting plasma glucose (mmol/l) x fasting serum 
insulin(mU/L)/22.5. Glomerular filtration rate (GFR) was estimated using the four component 
abbreviated equation from the MDRD Study [15]. 
Serum NT-proBNP levels were measured by a two-site sandwich electrochemiluminescence 
immunoassay (Elecsys proBNP II, Roche Diagnostic, Mannheim, Germany), using a Modular 
Analytics Evo analyzer with a E170 module (Roche) as we have previously described [16]. The 
intra-assay variation was below 3.0% and total CV ranges between 2.2 and 5.8% in low and high 
ranges of NT-proBNP. 
     Data were expressed as mean (SD) or geometric means (inter-quartile range). Logistic regression 
analysis was used to estimate the odds ratios (ORs) of serum NT-proBNP levels for MetS. We 
estimated ORs of log-NT-proBNP and across its quartiles (model 1), after adjustment for age and 
sex (model 2) and after further adjustment for log-AER, log-CRP and eGFR (model 3), waist 
circumference (model 4) and log-HOMA (model 5). We also examined the role of other variables 
(treatment with ACE/ARB inhibitors, diuretics  and other antihypertensive treatment, statins, BMI, 
and uric acid), which were retained in the final model if they added significantly to the likelihood of 
models or to the estimated coefficients of predictors. To assess pattern of ORs across increasing 
serum NT-proBNP levels, we constructed both models for log-NTproBNP values as a continuous 
measure - assessing the multiplicative increase of each increment of NTproBNP to risk of MetS - 
and models with quartiles of NT-proBNP, according to the values distribution among control 
subjects. We tested for linear trends across quartiles by entering a single ordinal term into the 
models. As ORs in the lower NT-proBNP quartiles were similar, they were aggregated as the 
reference category in the final analyses and compared with the upper quartile. P value of less than 
0.05 was considered to indicate statistical significance. Analyses were performed with Stata (Stata 
Release 10.0, Stata Corporation, College Station, Texas). 
 
Results  
     The study population (n=285) had a mean age of 58.1 years (SD 8.4). As shown in Table 1, 
cases were older than controls and had a greater proportion of men. As expected, mean waist 
circumference, BMI, systolic and diastolic blood pressure, blood glucose, insulin, HOMA and 
triglyceride levels were greater, while HDL-cholesterol levels lower in cases than in controls. Cases 
also had a more adverse cardiovascular risk profile with significantly higher values of LDL-
cholesterol, apoB, hs-CRP, and AER. 
As shown in Figure 1, NT-proBNP values showed a right skewed distribution  and were 
significantly higher in cases than in control subjects (Table 1). In 8 (6.4%) control subjects and 36 
(22.4%) cases NT-proBNP values were 100 pg/ml and over. Comparing subjects with and without 
each component of the MetS, we found that NT-proBNP values were significantly higher in 
subjects having IFG (39.02 vs 25.57 ng/ml, p=0.006), central obesity (37.90 vs 24.80, p=0.004), 
and hypertension (36.10 vs 23.69 ng/ml, p=0.005), whereas they were unaffected by the presence of  
dyslipidemia (30.44 vs 29.87 ng/ml, p=0.90).  Examined subjects had either no component or two 
or more one components of the MetS and NTproBNP values were higher with increasing numbers 
of components of the MetS (Figure 2).  
      We then performed logistic regression analyses to assess whether higher NT-proBNP values 
conferred increased odds ratio of having the MetS, independently of main risk factors (Table 2). 
Models showed that higher levels of NT-proBNP conferred greater OR for the MetS (model 1). 
This association remained statistically significant after further adjustments for age and sex (model 
2). With respect to NT-proBNP values ≤ 49.64 ng/ml, higher values conferred a 2.4 fold increased 
odds of having the MetS (OR=2.43, 95% CI 1.28-4.60). The strength of the association between 
NT-proBNP and MetS was virtually unmodified after further adjustment for AER, CRP and eGFR 
(model 3), while a negative confounding effect of waist circumference was evident (model 4). 
Indeed, after further adjustment for central obesity, OR increased to 4.17 (1.30-13.44). In contrast, 
further adjustment for log-HOMA did not modify the association (model 5). No effect on ORs of 
other examined variables, including drugs, was evident. 
       Models including either components of the MetS or systolic blood pressure could not be 
assessed due to overfitting of data, whereas  the inclusion of diastolic blood pressure into model 3 
reduced only slightly OR conferred by NT-proBNP >49.64 ng/ml (OR=3.28, 1.17-9.25). Logistic 
regression analysis was then performed in cases (n=15) and control subject (n=122) who were 
normotensive at the examination. Even in this subgroup of subjects, compared to NTproBNP values 
≤49.64 ng/ml, higher values  conferred an adjusted OR  (model 3) of  6.64 (95% CI 1.14-38.14), 
which remained statistically significant even after adjustments for diastolic blood pressure.   
 
Discussion 
The present analysis of the Casale Monferrato Study shows that people with uncomplicated 
MetS had greater NT-proBNP levels than people without any component of the MetS. Indeed, NT-
proBNP values were two-fold higher in cases than in control subjects, though absolute values were 
still in the low range. After adjustment for central obesity, people with the MetS had a 4-fold higher 
odds of having NT-proBNP values in the highest quartile (>49.64 pg/ml) than those with lower 
values. This finding was independent of main risk factors and confounders, including age, sex, 
AER, CRP, eGFR, and waist circumference and it was evident even in normotensive subjects. The 
insulin-resistance state did not mediate this association as no changes in ORs were observed after 
inclusion of the variable HOMA in the fully adjusted multivariate model.  
As we excluded from our analyses all subjects with low-grade inflammation (plasma CRP ≥ 
3 g/l) and CKD, we reduced the likelihood of a potential confounding effect of both inflammatory 
processes and reduced renal function on NT-proBNP levels. Therefore, our finding likely reflects 
the underlying chronic cardiovascular stress due to the presence of the defining components of the 
MetS. In our cohort hypertension was highly prevalent, with 90% of cases with MetS being 
hypertensive, compared to only 2% of control subjects. Moreover, mean diastolic blood pressure 
values were quite high in cases, indicating an overall poor blood pressure control. However, our 
results were confirmed even limiting the analysis to normotensive subjects and after further 
adjustment for diastolic blood pressure, suggesting that other mechanisms are also involved in BNP 
increase. NPs have important physiological effects on cardiovascular system, body fluids, and 
electrolytic homeostasis [17]. Moreover, they have a well-known protective action on the vascular 
endothelium, reducing shear stress, modulating both coagulative and fibrinolytic cascades, and 
inhibiting platelet activation [18]. It is thus likely that the higher NT-proBNP values in 
uncomplicated patients with MetS reflect the presence of multiple risk factors, which define the 
cardiovascular risk status of individual subjects, and may help to predict the CV risk of 
asymptomatic people. Consistently, we have recently shown that in diabetic people of the Casale 
Monferrato cohort, a slight increase in NT-proBNP levels was a strong independent predictor of CV 
mortality even in patients without pre-existing CVD [19]. Moreover, among patients at risk of heart 
failure, BNP-based screening and collaborative care allowed to reduce the combined rates of left 
ventricular systolic dysfunction, diastolic dysfunction, and heart failure [20].  
As shown in table 3, previous studies assessing the relationship between NT-proBNP values 
and the MetS were conflicting [11-13]. Nonetheless, the literature generally refers to people with 
the MetS as having lower plasma NT-proBNP values compared to those without the MetS. 
However, inconsistencies among studies might be explained by the recruitment of cohorts with 
different prevalence of obese subjects due to the negative association between obesity and NT-
proBNP. In our study, mean values of BMI and waist circumference were lower than in other 
Caucasians and higher than among Asians. As a consequence, the relative frequency of 
hypertension was higher than in other studies performed on people with the MetS. Finally, we 
recruited only subjects without CVD and we performed the analyses on subjects in the 
uncomplicated phase of the MetS. Therefore, our study adds to previous knowledge on this issue, 
providing evidence that in patients in the early phase of the MetS, including in those without 
hypertension, NT-proBNP is increased, thus representing an early marker of potential clinical 
utility.  
Our study confirms previous data on the negative confounding effect of obesity on NT-
proBNP values [21]. The cause of the relative NP deficiency seen in obese persons is poorly 
understood. It has been postulated that there is increased BNP clearance by the adipose tissue in 
obese subjects. However, there is evidence that NT-proBNP is predominantly cleared by the kidney 
[22].  
A recent study has shown that low NT-pro-BPN levels are a potent predictor of Type 2 
diabetes onset [4]. However, in our study, subjects with uncomplicated MetS, a known risk factor 
for the development of type 2 diabetes, had greater NP-proBNP levels. The explanation of this 
finding is unclear, however, experimental studies have demonstrated a role of NP on adipose tissue 
metabolism and on central control of energy balance. Indeed, NPs exert potent lipolytic effects 
mediated by the NP receptor type A/cGMP pathway in human fat cells and they contribute to lipid 
mobilization in vivo. A browning of white fat and thermogenesis has also been shown. Moreover, 
NPs also enhance oxidative capacity and fat oxidation in skeletal muscle of mice and humans, and 
cardiac NPs have emerged as potent metabolic hormones [7,8, 23]. It is thus temping to speculate 
that the rise in NT-proBNP levels in MetS is a compensatory mechanism and that among subjects 
with MetS the risk of type 2 diabetes is greater in those with insufficient compensatory ability. 
However, causal relationships cannot be inferred in a cross-sectional study and further studies are 
required to address this hypothesis.  
  Strengths of our study include the identification of both cases and control subjects within a 
population-based cohort, thus allowing to prevent selection bias; the standardized data collection, 
allowing to exclude detection bias; the exclusion criteria, allowing to provide data on apparently 
healthy subjects with the MetS.  
There are certain limitations to our study. First, this is a cross-sectional study and this restricts our 
ability to assess temporal relationships between NT-proBNP and MetS and to identify causal 
biological mechanisms underlying this association. Second, the presence of CVD was assessed 
based on clinical data and resting ECG. Therefore, we cannot exclude the possibility that some 
patients with CVD and normal ECG were erroneously included. However, the WHO Rose 
questionnaire was administered and people with symptoms suggestive of CVD underwent further 
investigations before inclusion in our survey. Third, although the population-based Casale 
Monferrato cohort was quite large, only 161 cases and 125 controls could be compared applying  
exclusion criteria. The subgroup of normotensive subjects was even smaller. However, adjusted OR 
of NTproBNP in the upper quartile still remained significantly associated with the risk of having the 
MetS and this finding was unchanged after further adjustment for diastolic blood pressure. 
Moreover, the ratio of normotensive cases compared to control subjects was more than 1 to 7, 
which allowed us to provide quite robuste data.  We therefore believe that our results represent a 
starting point for studies based on larger numbers of subjects.  
In conclusion, our case-cohort study within the population-based Casale Monferrato Study 
provided evidence that, compared to people without any component of the MetS, those in the 
uncomplicated phase of the MetS, who had neither CVD/CKD nor diabetes, had yet increased NT-
proBNP values, even if they were normotensive. The insulin-resistance state did not mediate this 
association, while central obesity was a negative confounder. Further prospective studies of large 
cohorts are need to further explore the role of NTproBNP in the MetS.   
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Table 1. Physical and clinical characteristic of case and control subjects of the Casale 
Monferrato Study 
 
 Case subjects Control subjects P 
N 161 124  
Age (years) 61.0 ± 8.0 54.5 ± 6.5 <0.0001 
Males (%) 98 (60.9%) 24 (19.3%) <0.0001 
BMI
 
(kg/m
2
) 29.4 ± 4.5 22.3 ± 2.7 <0.0001 
 <25 24 (13.3%) 115 (84.6%) <0.001 
25-29 84 (46.7%) 19 (14.0%)  
>29 72 (40.0%) 2 (1.5%)  
Waist circumference (cm) 100.6 ± 9.8 76.4± 8.9 <0.0001 
Systolic blood pressure (mmHg)
 
 153.7 ± 18.7  118.4 ± 10.3 <0.0001 
Diastolic blood pressure  (mmHg)  94.6 ± 10.8  77.1 ± 6.7 <0.0001 
Hypertension (%)  146 (90.7%) 2 (1.6%) <0.0001 
Total cholesterol (mmol/l)  5.77 ± 1.05 5.45 ± 0.83 0.006 
LDL-cholesterol (mmol/l)  3.34 ± 0.93 3.05 ± 0.70 0.004 
HDL-cholesterol (mmol/l) 1.51 ± 0.36 2.00 ± 0.43 <0.0001 
Triglycerides (mmol/l) 1.90 (1.46-2.44) 0.84 (0.69-1.01) <0.0001 
ApoB (mg/dl) 106.8 ± 26.4 87.8 ± 18.9 <0.0001 
Glucose (mg/dl) 102.0 ± 10.9 86.1 ± 7.7 <0.0001 
HOMA 3.34 (2.34-4.74) 1.27 (0.95-1.89) <0.0001 
Insulin (ng/ml) 13.4 (10.2-19.0) 6.0 (4.7-8.4) <0.0001 
AER g/min 51.1 (25.8-78.1) 32.3 (19.0-47.8) <0.0001 
CRP (mg/l)  1.3 (0.9-2.0) 0.79 (0.5-1.2)   <0.0001 
eGFR (60 ml/min/1.73m
2 
) 84.5 (76.0-102.3) 90.7 (84.0-100.0) <0.0001 
Smokers                                      no 87 (54.8%) 68 (54.8%) 0.19 
                                                     ex 45 (20.2%) 25 (20.2%)  
                                                    yes 29 (18.0%) 31 (25.0%)  
NT-proBNP (pg/ml) 35.4 (15.5-98.2) 24.4 (11.7-49.6) 0.014 
<11.73 37 (23.0%) 31 (25%) 0.012 
                             11.73-27.62 30 (18.6%) 31(25%)  
                                27.63-49.64 25 (15.5%) 31(25%)  
                                   >49.64 69 (42.9%) 31(25%)  
 
 
Table 2: Odds ratios for the metabolic syndrome by NT-proBNP values in the case-cohort 
study of the Casale Monferrato Study 
 
 
 
 Model 1 Model 2 Model 3 Model 4 Model 5 
 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Log-NT-proBNP 1.27 (1.05-1.54)  1.29 (1.00-1.66) 1.22 (0.93-1.61) 1.47 (0.92-2.34) 1.56 (0.91-2.68) 
NT-proBNP    (ng/ml)       
<11.73 1.00 1.00 1.00 1.00 1.00 
                             11.73-27.62    0.81 (0.41-1.62) 0.97 (0.42-2.22) 1.02 (0.43-2.44) 0.55 (0.14-2.11) 0.65 (0.13-3.34) 
                                27.63-49.64 0.68 (0.33-1.38) 0.66 (0.27-1.60) 0.46 (0.18-1.18) 0.51 (0.10-2.57) 0.48 (0.06-3.83) 
                                   >49.64 1.86 (0.99-3.53) 2.11 (0.94-4.73) 1.97 (0.82-4.72) 2.85 (0.71-11.38) 3.39 (0.67-17.3) 
P for trend 0.05 0.08 0.22 0.12 0.15 
      
NT-proBNP (ng/ml)     ≤49.64 1.00 1.00 1.00 1.00 1.00 
                                       >49.64 2.25 (1.35-3.76) 2.43 (1.28-4.60) 2.51 (1.26-5.00) 4.17 (1.30-13.44) 4.62 (1.17-18.32) 
 
 
Model 1: unadjusted.  
Model 2: adjusted for age and sex.  
Model 3: adjusted for age, sex, AER, eGFR, CRP  
Model 4: adjusted for age, sex, AER, eGFR, CRP and waist circumference 
Model 5: adjusted for age, sex, AER, eGFR, CRP, waist circumference and log-HOMA-IR
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Table 3: Comparison  of study designs and main results of studies examining the association between NT-proBNP levels and the MetS  
 
 
NT-proBNP: N-terminal pro-B-type natriuretic peptide; MetS: metabolic syndrome; EGIR: European Group for the Study of Insulin resistance; 
SBP: systolic blood pressure; DBP: diastolic blood pressure; FBG: fasting blood glucose; LVMI: left ventricular mass index, LVEF: left ventricular 
ejection fraction, CVD: Cardiovascular Disease;  eGFR: estimated glomerular filtration rate; AER: albumin excretion rate; CRP: C-reactive protein 
 
Study  Study design Variables Main findings 
Olsen MH & al, 
2005  (13) 
Population-based study in Denmark,  
subjects without CVD (n=2070)  
recruited in 1992-93,  MetS (n=318) 
defined by EGIR criteria 
 
 
 
 
  
Age, gender, daily exercise,  
alcohol consumption, 
smoking status, BMI, waist 
circumference, lipids, FBG, 
insulin, heart rate, SBP, DBP  
Nt-proBNP levels were lower in people with the 
MetS, attributable to the inverse relationships 
between serum NT-proBNP and BMI, serum insulin, 
and cholesterol.   
The MetS shifted the positive relationship between 
pulse pressure and Nt-proBNP to the right (ie, higher 
blood pressure for a given level of Nt-proBNP) 
 
Bao Y & al, 
2011 (11) 
Case-control study in China, 
 cases (n=230) and control subjects 
(n=239) recruited at an endocrinology 
clinic 
Age, gender, BMI, SBP, DBP, 
FBG, lipids, LDLc, LVMI, 
LVEF 
NT-proBNP levels were lower in people with the 
MetS compared with those without  the MetS  
Li W-Y & al,  
2011 (12) 
Case-control study in Taiwan,  
cases (n. 270) and control subjects 
(n=270) recruited among those 
referred to a clinic, matched by their  
propensity score 
BMI, waist circumference, 
SBP, DBP, FBG, lipids, 
insulin 
No difference in NT-proBNP levels between cases 
and control subjects 
Present study  Case-cohort study within a 
population-based study in Italy, 
uncomplicated cases of MetS (n= 161) 
and control subjects with no 
component of the MetS (n=124) 
Age, gender, waist 
circumference, eGFR, SBP, 
DBP,  lipids, AER,  CRP, 
HOMA-IR 
NT-proBNP levels were higher in  people with the 
MetS than in those without it, even in the subgroup of 
normotensive subjects 
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